4.7 Article

Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory

期刊

NATURE NEUROSCIENCE
卷 17, 期 7, 页码 971-980

出版社

NATURE PORTFOLIO
DOI: 10.1038/nn.3728

关键词

-

资金

  1. US National Institutes of Health (NIH) [R37GM043880]
  2. NIH [P30CA16059]
  3. National Natural Science Foundation of China [91029704]
  4. [5P01DA009789]
  5. [R21AG042745]
  6. [R01NS057758]

向作者/读者索取更多资源

FTY720 (fingolimod), an FDA-approved drug for treatment of multiple sclerosis, has beneficial effects in the CNS that are not yet well understood, independent of its effects on immune cell trafficking. We show that FTY720 enters the nucleus, where it is phosphorylated by sphingosine kinase 2 (SphK2), and that nuclear FTY720-P binds and inhibits class I histone deacetylases (HDACs), enhancing specific histone acetylations. FTY720 is also phosphorylated in mice and accumulates in the brain, including the hippocampus, inhibits HDACs and enhances histone acetylation and gene expression programs associated with memory and learning, and rescues memory deficits independently of its immunosuppressive actions. Sphk2(-/-) mice have lower levels of hippocampal sphingosine-l-phosphate, an endogenous HDAC inhibitor, and reduced histone acetylation, and display deficits in spatial memory and impaired contextual fear extinction. Thus, sphingosine-l-phosphate and SphK2 play specific roles in memory functions and FTY720 may be a useful adjuvant therapy to facilitate extinction of aversive memories.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据